{"text_format":"3","workbook":"xlsx","n_sheets":2,"sheets":["西药","中成药"],"not_rendered":{"defined_names":4},"read":"whole","date_system":"1900"}

{"sheet":"西药","index":0,"n_rows":363,"n_cols":13,"rows_kept":363,"merged":[[0,0,0,11],[1,0,2,0],[1,1,2,5],[1,6,2,6],[1,7,2,7],[1,8,2,8],[1,9,2,9],[1,10,2,10],[1,11,2,11],[1,12,2,12],[3,1,3,5],[4,2,4,7],[6,4,6,6],[20,3,20,6],[99,2,99,7],[100,3,100,7],[103,3,103,7],[134,4,134,7],[201,4,201,7],[286,4,286,7],[327,2,327,7]]}
["湖北省“双通道”及“单独支付”药品目录（2022年版）\n（一）西药"]
["药品分类代码","药品分类",{"$nulls":4},"编号","药品名称","医保支付标准","医保支付标准","备注","是否单独支付","是否申请保密"]
[]
["XA","消化道和代谢方面的药物"]
["XA02",null,"治疗胃酸相关类疾病的药物"]
["XA02B",null,null,"治疗消化性溃疡病和胃食道反流病的药物"]
["XA02BC",{"$nulls":3},"质子泵抑制剂"]
[{"$nulls":5},"乙",1,"注射用艾普拉唑钠","71元（10mg/支）","71元（10mg/支）","消化性溃疡出血。","否"]
["XA02BX",{"$nulls":3},"其他治疗消化性溃疡病和胃食道反流病的药物"]
[{"$nulls":5},"乙",2,"富马酸伏诺拉生片","*；","*","限反流性食管炎的患者。","否","是"]
["XA04",null,"止吐药和止恶心药"]
[{"$nulls":5},"乙",3,"甲磺酸多拉司琼注射液","13.6元(1ml:12.5mg/支)；\n66.82元(5ml:100mg/支)","13.6元(1ml:12.5mg/支)；\n66.82元(5ml:100mg/支)","限放化疗且吞咽困难患者。","否"]
["XA05",null,"胆和肝治疗药",{"$nulls":3},""]
["XA05B",null,null,"肝脏治疗药，抗脂肪肝药"]
[{"$nulls":5},"乙",4,"甘草酸单铵半胱氨酸氯化钠注射液","40元(100ml/瓶)；\n81.16元(250ml/瓶)","40元(100ml/瓶)；\n81.16元(250ml/瓶)","限肝功能衰竭或无法使用甘草酸口服制剂的患者。","否"]
[{"$nulls":5},"乙",5,"精氨酸谷氨酸注射液","54元(200ml:20g/瓶)；\n54元(200ml:20g/袋)","54元(200ml:20g/瓶)；\n54元(200ml:20g/袋)","限肝性脑病。","否"]
[{"$nulls":5},"乙",6,"门冬氨酸鸟氨酸颗粒","1.70元（1g/袋）；\n3.95元（3g/袋）","1.70元（1g/袋）；\n3.95元（3g/袋）","治疗因急、慢性肝病如肝硬化、脂肪肝、肝炎所致的高血氨症，特别适合治疗早期的意识失调或神经系统并发症。","否"]
["XA06",null,"治疗便秘药物"]
[{"$nulls":5},"乙",7,"利那洛肽胶囊","*；","*","限成人便秘型肠易激综合征(IBS-C)。","否","是"]
["XA10",null,"糖尿病用药",{"$nulls":3},""]
["XA10A",null,null,"胰岛素及其类似药物"]
["XA10AC",{"$nulls":3},"胰岛素及其类似物，中效"]
[{"$nulls":5},"乙",8,"德谷门冬双胰岛素注射液","*；","*","限其他胰岛素或口服药难以控制的2型糖尿病患者。","否","是"]
["XA10B",null,null,"降血糖药物，不含胰岛素"]
["XA10BD",{"$nulls":3},"口服复方降糖药"]
[{"$nulls":5},"乙",9,"二甲双胍恩格列净片（Ⅰ）","1.21元（每片含盐酸二甲双胍500mg与恩格列净5mg）","1.21元（每片含盐酸二甲双胍500mg与恩格列净5mg）","本品配合饮食控制和运动，适用于正在接受恩格列净和盐酸二甲双胍治疗的2型糖尿病成人患者，用于改善这些患者的血糖控制。","否"]
["XA10BF",{"$nulls":3},"α-葡萄糖苷酶抑制剂"]
[{"$nulls":5},"乙",10,"阿卡波糖咀嚼片","0.465元(50mg/片)","0.465元(50mg/片)",null,"否"]
["XA10BJ",{"$nulls":3},"胰高血糖素样肽-1(GLP-1)类似物"]
[{"$nulls":5},"乙",11,"艾塞那肽注射液","*；","*","限二甲双胍等口服降糖药或胰岛素控制效果不佳的BMI≥25的患者，首次处方时需由二级及以上医疗机构专科医师开具处方。","否","是"]
[{"$nulls":5},"乙",12,"利拉鲁肽注射液","*；","*","限二甲双胍等口服降糖药或胰岛素控制效果不佳的BMI≥25的患者，首次处方时需由二级及以上医疗机构专科医师开具处方。","否","是"]
[{"$nulls":5},"乙",13,"利司那肽注射液","*；","*","限二甲双胍等口服降糖药或胰岛素控制效果不佳的BMI≥25的患者，首次处方时需由二级及以上医疗机构专科医师开具处方。","否","是"]
[{"$nulls":5},"乙",14,"贝那鲁肽注射液","*；","*","限二甲双胍等口服降糖药或胰岛素控制效果不佳的BMI≥25的患者，首次处方时需由二级及以上医疗机构专科医师开具处方。","否","是"]
[{"$nulls":5},"乙",15,"度拉糖肽注射液","*；","*","限二甲双胍等口服降糖药或胰岛素控制效果不佳的BMI≥25的患者，首次处方时需由二级及以上医疗机构专科医师开具处方。","否","是"]
[{"$nulls":5},"乙",16,"聚乙二醇洛塞那肽注射液","110元(0.5ml:0.1mg/支)；\n187元(0.5ml:0.2mg/支)","110元(0.5ml:0.1mg/支)；\n187元(0.5ml:0.2mg/支)","限二甲双胍等口服降糖药或胰岛素控制效果不佳的BMI≥25的患者，首次处方时需由二级及以上医疗机构专科医师开具处方。","否"]
[{"$nulls":5},"乙",17,"司美格鲁肽注射液","*；","*","本品适用于成人2型糖尿病患者的血糖控制：在饮食控制和运动基础上，接受二甲双胍和/或磺脲类药物治疗血糖仍控制不佳的成人2型糖尿病患者。适用于降低伴有心血管疾病的2型糖尿病成人患者的主要心血管不良事件（心血管死亡、非致死性心肌梗死或非致死性卒中）风险。","否","是"]
["XA10BK",{"$nulls":3},"钠葡萄糖协同转运蛋白2(SGLT-2)抑制剂"]
[{"$nulls":5},"乙",18,"达格列净片","*；","*","限2型糖尿病成人患者的二线用药。","否","是"]
[{"$nulls":5},"乙",19,"艾托格列净片","*；","*","限二线用药。","否","是"]
["XA16",null,"其他消化道及代谢用药"]
[{"$nulls":5},"乙",20,"麦格司他胶囊","*；","*","限C型尼曼匹克病患者。","是","是"]
[{"$nulls":5},"乙",21,"盐酸乙酰左卡尼汀片","0.58元(0.25g/片)；\n0.99元(0.5g/片)","0.58元(0.25g/片)；\n0.99元(0.5g/片)","限临床确诊的糖尿病周围神经病变患者。","否"]
[{"$nulls":5},"乙",22,"注射用维得利珠单抗","*；","*","限中度至重度活动性溃疡性结肠炎的二线用药或中度至重度活动性克罗恩病的二线用药。","是","是"]
[{"$nulls":5},"乙",23,"阿加糖酶α注射用浓溶液","*；","*","本品用于确诊为法布雷病（α-半乳糖苷酶A缺乏症）患者的长期酶替代治疗。本品适用于成人、儿童和青少年。尚未确定本品在0-6岁儿童中的安全性和有效性。","是","是"]
["XB","血液和造血器官药"]
["XB01",null,"抗血栓形成药"]
["XB01A",null,null,"抗血栓形成药"]
["XB01AC",{"$nulls":3},"血小板凝聚抑制剂，肝素除外"]
[{"$nulls":5},"乙",24,"司来帕格片","*；","*","限WHO功能分级II级-III级的肺动脉高压（WHO第1组）的患者。","是","是"]
[{"$nulls":5},"乙",25,"铝镁匹林片(Ⅱ)","1.5元(每片含阿司匹林81mg,重质碳酸镁22mg,甘羟铝11mg)","1.5元(每片含阿司匹林81mg,重质碳酸镁22mg,甘羟铝11mg)",null,"否"]
["XB01AD",{"$nulls":3},"酶类"]
[{"$nulls":5},"乙",26,"注射用重组人组织型纤溶酶原激酶衍生物","*；","*","限急性心肌梗死发病12小时内使用。","否","是"]
[{"$nulls":5},"乙",27,"注射用重组人尿激酶原","508元(5mg/支)","508元(5mg/支)","限急性心肌梗死发病12小时内使用。","否"]
[{"$nulls":5},"乙",28,"注射用阿替普酶","*；","*","限急性心肌梗死发病12小时内、脑梗死发病3小时内的溶栓治疗，超过说明书规定用药时限的不予支付。","否","是"]
[{"$nulls":5},"乙",29,"注射用重组人TNK组织型纤溶酶原激活剂","3688元(1.0×10E7IU/16mg/支)","3688元(1.0×10E7IU/16mg/支)","限急性心肌梗死发病6小时内使用。","否"]
["XB01AF",{"$nulls":3},"直接Xa因子抑制剂"]
[{"$nulls":5},"乙",30,"甲苯磺酸艾多沙班片","6.26元(15mg/片)；\n10.65元(30mg/片)；\n18.11元(60mg/片)","6.26元(15mg/片)；\n10.65元(30mg/片)；\n18.11元(60mg/片)","限华法林治疗控制不良或出血高危的非瓣膜性房颤、深静脉血栓、肺栓塞患者。","否"]
["XB02",null,"抗出血药"]
["XB02B",null,null,"维生素K和其他止血药"]
[{"$nulls":5},"乙",31,"注射用重组人凝血因子Ⅶa","*；","*","用于下列患者群体出血的治疗，以及外科手术或有创操作出血的防治：\n1.凝血因子VIII或IX的抑制物>5个Bethesda单位（BU）的先天性血友病患者；预计对注射凝血因子VIII或凝血因子IX，具有高记忆应答的先天性血友病患者；2.获得性血友病患者；3.先天性凝血因子VII（FVII）缺乏症患者；4.具有血小板膜糖蛋白IIb－IIIa（GPIIb－IIIa）和/或人白细胞抗原（HLA）抗体和既往或现在对血小板输注无效或不佳的血小板无力症患者。","是","是"]
[{"$nulls":5},"乙",32,"重组人血小板生成素注射液","*；","*","限实体瘤化疗后所致的严重血小板减少症或特发性血小板减少性紫癜。","是","是"]
[{"$nulls":5},"乙",33,"注射用尖吻蝮蛇血凝酶","*；","*","限出血性疾病治疗的二线用药；预防使用不予支付。","否","是"]
[{"$nulls":5},"乙",34,"马来酸阿伐曲泊帕片","*；","*","限择期行诊断性操作或者手术的慢性肝病相关血小板减少症的成年患者。","是","是"]
[{"$nulls":5},"乙",35,"人凝血因子Ⅸ","*；","*","用于凝血因子Ⅸ缺乏症（B型血友病）患者的出血治疗。","是","是"]
[{"$nulls":5},"乙",36,"艾曲泊帕乙醇胺片","*；","*","本品适用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的成人和12岁及以上儿童慢性免疫性（特发性）血小板减少症（ITP）患者，使血小板计数升高并减少或防止出血。本品仅用于因血小板减少和临床条件导致出血风险增加的ITP患者。","是","是"]
[{"$nulls":5},"乙",37,"海曲泊帕乙醇胺片","*；","*","1.本品适用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症(ITP)成人患者，使血小板计数升高并减少或防止出血。本品仅用于因血小板减少和临床条件导致出血风险增加的ITP患者。\n2.本品适用于对免疫抑制治疗（IST）疗效不佳的重型再生障碍性贫血（SAA）成人患者。基于一项II期单臂试验的结果附条件批准本适应症。该适应症的完全批准将取决于正在进行的确证性临床试验的结果。","是","是"]
["XB03",null,"抗贫血药"]
["XB03B",null,null,"维生素B12和叶酸"]
[{"$nulls":5},"乙",38,"罗沙司他胶囊","*；","*","本品适用于慢性肾脏病(CKD)引起的贫血, 包括透析及非透析患者。","否","是"]
["XB05",null,"血液代用品和灌注液"]
["XB05B",null,null,"静脉注射液"]
["XB05BA",{"$nulls":3},"胃肠外营养液"]
[{"$nulls":5},"乙",39,"多种油脂肪乳(C6～24)注射液","*；","*","限经营养风险筛查，明确具有营养风险的肝功能不全（严重肝功能不全者除外）患者的二线用药。消化道有功能患者使用时不予支付。","否","是"]
[{"$nulls":5},"乙",40,"复方氨基酸注射液(18AA-Ⅴ-SF)","24.15元（100ml:3.224g（总氨基酸）与5g木糖醇/瓶）；\n48.70元（250ml:8.06g（总氨基酸）与12.5g木糖醇）；\n82.79元（500ml:16.12g（总氨基酸）与25g木糖醇）","24.15元（100ml:3.224g（总氨基酸）与5g木糖醇/瓶）；\n48.70元（250ml:8.06g（总氨基酸）与12.5g木糖醇）；\n82.79元（500ml:16.12g（总氨基酸）与25g木糖醇）","用于营养不良，低蛋白血症及外科手术前后。","否"]
[{"$nulls":5},"乙",41,"复方氨基酸注射液（14AA-SF）","37.40元（50ml:4.2g（总氨基酸）/瓶）；\n129.16元（250ml:21.2g（总氨基酸）/瓶）","37.40元（50ml:4.2g（总氨基酸）/瓶）；\n129.16元（250ml:21.2g（总氨基酸）/瓶）","用于改善手术前后病人营养状态，亦用于蛋白质消化和吸收障碍，蛋白质摄取量不足或消耗过多等所致的轻度营养不良。","否"]
["XB06",null,"其他血液系统用药"]
["XB06A",null,null,"其他血液系统用药"]
["XB06AC",{"$nulls":3},"遗传性血管性水肿药物"]
[{"$nulls":5},"乙",42,"醋酸艾替班特注射液","*；","*","用于治疗成人、青少年和≥2岁儿童的遗传性血管性水肿（HAE）急性发作。","是","是"]
["XC","心血管系统"]
["XC01",null,"心脏治疗药"]
["XC01C",null,null,"强心苷类除外的心脏兴奋药"]
[{"$nulls":5},"乙",43,"盐酸奥普力农注射液","198元(5ml:5mg/支)","198元(5ml:5mg/支)","限其他药物疗效不佳的急性心力衰竭的短期静脉治疗。","否"]
["XC01E",null,null,"其他心脏疾病用药"]
[{"$nulls":5},"乙",44,"注射用重组人脑利钠肽","445元(0.5mg/支)","445元(0.5mg/支)","限二级及以上医疗机构用于规范治疗效果不佳的急性失代偿性心力衰竭短期治疗，单次住院支付不超过3天。","否"]
[{"$nulls":5},"乙",45,"丹参酮ⅡA磺酸钠注射液","11.9元(2ml:10mg/支)","11.9元(2ml:10mg/支)","限明确冠心病稳定型心绞痛诊断的患者，支付不超过14天。","否"]
["XC02K",null,null,"其他抗高血压药"]
[{"$nulls":5},"乙",46,"波生坦片","*；","*","限WHO功能分级II级-IV级的肺动脉高压（WHO第1组）的患者。","是","是"]
[{"$nulls":5},"乙",47,"波生坦分散片","*；","*","限3-12岁特发性或先天性肺动脉高压患者。","是","是"]
[{"$nulls":5},"乙",48,"利奥西呱片","*；","*","限以下情况方可支付：1.术后持续性或复发性慢性血栓栓塞性肺动脉高压（CTEPH）或不能手术的CTEPH，且（WHO FC）为II-III的患者；2.动脉性肺动脉高压（PAH）且（WHO FC）为II-III患者的二线用药。","是","是"]
[{"$nulls":5},"乙",49,"马昔腾坦片","*；","*","限WHO功能分级II级-III级的肺动脉高压（WHO第1组）的患者。","是","是"]
["XC07","β-受体阻滞剂"]
["XC07A",null,"β-受体阻滞剂"]
["XC07AB",null,null,"选择性β-受体阻滞剂"]
[{"$nulls":5},"乙",50,"注射用盐酸兰地洛尔","168元（50mg/支）","168元（50mg/支）","1.手术过程中发生的下列快速性心律失常的紧急治疗：心房纤颤、心房扑动、窦性心动过速。2.手术后循环系统动态监护时发生的快速性心律失常的紧急治疗：心房纤颤、心房扑动、窦性心动过速。3.心功能不全患者发生下列快速性心律失常的治疗：心房纤颤、心房扑动。","否"]
["XC08",null,"钙通道阻滞剂"]
["XC08C",null,null,"主要作用于血管的选择性钙通道阻滞剂"]
["XC08CA",{"$nulls":3},"二氢吡啶衍生物类"]
[{"$nulls":5},"乙",51,"氨氯地平叶酸片（II）","1.58元（每片含苯磺酸氨氯地平5mg(以氨氯地平计)与叶酸0.8mg）","1.58元（每片含苯磺酸氨氯地平5mg(以氨氯地平计)与叶酸0.8mg）","用于治疗伴有血浆同型半胱氨酸水平升高的原发性高血压。氨氯地平降低血压，叶酸降低血同型半胱氨酸水平，升高血叶酸水平。","否"]
["XC09",null,"作用于肾素-血管紧张素系统的药物"]
["XC09C",null,null,"血管紧张素Ⅱ拮抗剂的单方药"]
[{"$nulls":5},"乙",52,"阿利沙坦酯片","*；","*","用于轻、中度原发性高血压的治疗。","否","是"]
[{"$nulls":5},"乙",53,"阿齐沙坦片","*；","*","高血压。","否","是"]
["XC09D",null,null,"血管紧张素Ⅱ拮抗剂的复方制剂"]
[{"$nulls":5},"乙",54,"沙库巴曲缬沙坦钠片","*；","*","1.以沙库巴曲缬沙坦计50mg、100mg、200mg：用于射血分数降低的慢性心力衰竭(NYHA Ⅱ-Ⅳ级，LVEF≤40%)成人患者，降低心血管死亡和心力衰竭住院的风险。沙库巴曲缬沙坦钠片可代替血管紧张素转化酶抑制剂(ACEI)或血管紧张素Ⅱ受体拮抗剂(ARB)，与其他心力衰竭治疗药物合用。2.以沙库巴曲缬沙坦计100mg、200mg：用于治疗原发性高血压。","否","是"]
["XC10","调节血脂药"]
["XC10A",null,"单方调节血脂药"]
["XC10AX",null,null,"其他调节血脂药"]
[{"$nulls":5},"乙",55,"海博麦布片","6.7元（10mg/片）；\n11.39元（20mg/片）","6.7元（10mg/片）；\n11.39元（20mg/片）","本品作为饮食控制以外的辅助治疗，可单独或与HMG-CoA还原酶抑制剂（他汀类）联合用于治疗原发性（杂合子家族性或非家族性）高胆固醇血症，可降低总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、载脂蛋白B（Apo B）水平。","否"]
[{"$nulls":5},"乙",56,"依洛尤单抗注射液","*；","*","1.降低心血管事件的风险：在已有动脉粥样硬化性心血管疾病的成人患者中，降低心肌梗死、卒中以及冠脉血运重建的风险。通过：与最大耐受剂量的他汀类药物联合用药，伴随或不伴随其他降脂疗法，或者在他汀类药物不耐受或禁忌使用的患者中，单独用药或与其他降脂疗法联合用药。2.原发性高胆固醇血症（包括杂合子型家族性高胆固醇血症）和混合型血脂异常：可作为饮食的辅助疗法，用于成人原发性高胆固醇血症(杂合子家族性和非家族性)或混合型血脂异常患者的治疗，以降低低密度脂蛋白胆固醇(LDL-C)水平：在接受最大耐受剂量的他汀类药物治疗仍无法达到LDL-C目标的患者中，与他汀类药物、或者与他汀类药物及其他降脂疗法联合用药，或者在他汀类药物不耐受或禁忌使用的患者中，单独用药或与其他降脂疗法联合用药。3.纯合子型家族性高胆固醇血症：用于成人或12岁以上青少年的纯合子型家族性高胆固醇血症。可与饮食疗法和其他降低密度脂蛋白胆固醇（LDL-C）治疗（例如他汀类药物、依折麦布、LDL分离术）合用，用于患有纯合子型家族性高胆固醇血症（HoFH）且需要进一步降低LDL-C的患者。","是","是"]
[{"$nulls":5},"乙",57,"阿利西尤单抗注射液","*；","*","1.心血管事件预防：在确诊为动脉粥样硬化性心血管疾病的成人患者中，降低心肌梗死、卒中、需要住院的不稳定性心绞痛的风险。通过：与最大耐受剂量的他汀类药物联合用药，伴随或不伴随其他降脂疗法，或者在他汀类药物不耐受或禁忌使用的患者中，单独用药或与其他降脂疗法联合用药。2.原发性高胆固醇血症(包括杂合子型家族性和非家族性)和混合型血脂异常：可作为饮食的辅助疗法，用于成人原发性高胆固醇血症(杂合子型家族性和非家族性)或混合型血脂异常患者的治疗，以降低低密度脂蛋白胆固醇(LDL-C)水平。在接受最大耐受剂量的他汀类药物治疗仍无法达到LDL-C目标的患者中，与他汀类药物、或者与他汀类药物及其他降脂疗法联合用药，或者在他汀类药物不耐受或禁忌使用的患者中，单独用药或与其他降脂疗法联合用药。","是","是"]
["XD","皮肤病用药"]
["XD05",null,"治疗银屑病药"]
[{"$nulls":5},"乙",58,"本维莫德乳膏","138元(10g:0.1g/支)","138元(10g:0.1g/支)","限轻中度稳定性寻常型银屑病患者的二线治疗，需按说明书用药。","否"]
["XD11",null,"其他皮科制剂"]
[{"$nulls":5},"乙",59,"度普利尤单抗注射液","*；","*","限对传统治疗无效、有禁忌或不耐受的中重度特应性皮炎患者，需按说明书用药。","是","是"]
[{"$nulls":5},"乙",60,"克立硼罗软膏","*；","*","适用于2岁及以上轻度至中度特应性皮炎患者的局部外用治疗。","否","是"]
["XG","泌尿生殖系统药和性激素"]
["XG01",null,"妇科抗感染药和抗菌剂"]
["XG01A",null,null,"抗感染药和抗菌剂，与皮质激素类的复方制剂除外"]
["XG01AF",{"$nulls":3},"咪唑衍生物"]
[{"$nulls":5},"乙",61,"克霉唑阴道膨胀栓","7.98元（0.15g/粒）","7.98元（0.15g/粒）","用于念珠菌性外阴阴道病。","否"]
["XG04",null,"泌尿系统药"]
["XG04B",null,null,"泌尿系统药"]
[{"$nulls":5},"乙",62,"米拉贝隆缓释片","*；","*",null,"否","是"]
["XH","除性激素和胰岛素外的全身激素制剂"]
["XH01",null,"垂体和下丘脑激素及类似物"]
["XH01C",null,null,"下丘脑激素"]
["XH01CB",{"$nulls":3},"抗生长激素"]
[{"$nulls":5},"乙",63,"注射用醋酸奥曲肽微球","*；","*","限胃肠胰内分泌肿瘤、肢端肥大症，按说明书用药。","是","是"]
[{"$nulls":5},"乙",64,"醋酸兰瑞肽缓释注射液（预充式）","*；","*","限肢端肥大症，按说明书用药。","是","是"]
["XJ","全身用抗感染药"]
["XJ01",null,"全身用抗菌药"]
["XJ01M",null,null,"喹诺酮类抗菌药"]
["XJ01MB",{"$nulls":3},"其他喹诺酮类药"]
[{"$nulls":5},"乙",65,"苹果酸奈诺沙星胶囊","16.2元(250mg/粒)","16.2元(250mg/粒)","限二线用药。","否"]
[{"$nulls":5},"乙",66,"西他沙星片","9.8元(50mg/片)","9.8元(50mg/片)","限二线用药。","否"]
[{"$nulls":5},"乙",67,"苹果酸奈诺沙星氯化钠注射液","84.8元（250ml:苹果酸奈诺沙星0.5g和氯化钠2.25g/袋）","84.8元（250ml:苹果酸奈诺沙星0.5g和氯化钠2.25g/瓶）","为减少耐药菌的产生，保证奈诺沙星及其他抗菌药物的有效性，本品只用于治疗已证明或高度怀疑由敏感细菌引起的感染。在选择或修改抗菌药物治疗方案时，应考虑细菌培养和药敏试验的结果。如果没有这些试验的数据做参考，则应根据当地流行病学和病原菌敏感性进行经验性治疗。\n在治疗前应进行细菌培养和药敏试验以分离并鉴定感染病原菌，确定其对本品的敏感性。在获得以上检验结果之前可以先使用本品进行治疗，得到检验结果之后再选择适当的治疗方法。\n在此类中的其他药物相同，使用本品进行治疗时，在治疗期间应定期进行细菌培养和药敏试验以掌握病原菌是否对抗菌药物持续敏感，并在细菌出现耐药性后能够及时发现。\n本品可用于治疗对奈诺沙星呈现敏感的肺炎链球菌、金黄色葡萄球菌、流感嗜血杆菌、副流感嗜血杆菌、卡他莫拉菌、肺炎克雷伯菌、铜绿假单胞菌以及肺炎支原体、肺炎衣原体和嗜肺军团菌所致的成人(≥18岁)社区获得性肺炎。\n在使用本品时可依据患者病情严重程度及耐受性选用注射剂或口服制剂,也可选用治疗初期予以注射剂静脉输注,病情趋缓解后继以口服给药的序贯疗法。","否"]
["XJ01D",null,null,"其他β-内酰胺类抗菌药"]
[{"$nulls":5},"乙",68,"小儿法罗培南钠颗粒","15.3元(0.05g/袋)","15.3元(0.05g/袋)","限头孢菌素耐药或重症感染儿童患者。","否"]
[{"$nulls":5},"乙",69,"头孢托仑匹酯颗粒","*；","*","限儿童患者。","否","是"]
["XJ01X",null,null,"其他抗菌药"]
["XJ01XD",{"$nulls":3},"咪唑衍生物"]
[{"$nulls":5},"乙",70,"吗啉硝唑氯化钠注射液","97元(0.5g：100ml/瓶)","97元(0.5g：100ml/瓶)","限二线用药。","否"]
[{"$nulls":5},"乙",71,"注射用磷酸左奥硝唑酯二钠","25.18元（0.125g/支）","25.18元（0.125g/支）","为减少耐药菌的产生，保证磷酸左奥硝唑酯二钠、左奥硝唑、奥硝唑及其他抗菌药物的有效性，磷酸左奥硝唑酯二钠只用于治疗或预防已证明或高度怀疑由敏感细菌引起的感染。在选择或修改抗菌药物治疗方案时，应考虑细菌培养和药敏试验结果。如果没有这些试验的数据做参考，则应当根据当地流行病学和病原菌敏感性进行经验性治疗。\n在治疗前应进行细菌培养和药敏试验以分离并鉴定感染病原菌，确定其对该抗菌药物的敏感性，在获得以上药敏结果之前可以先使用该抗菌药物进行治疗，得到药敏结果后再选择进行针对病原菌的治疗。\n在治疗期间应定期进行细菌培养和药敏试验以掌握病原菌是否对抗菌药物持续敏感，并在细菌出现耐药性后能够及时发现。\n本品仅适用于不宜口服给药的患者。\n本品适应症为：\n1.本品适用于治疗肠道和肝脏严重的阿米巴病。2.本品适用于治疗奥硝唑敏感厌氧菌引起的手术后感染。3.本品适用于预防外科手术导致的敏感厌氧菌感染。","否"]
["XJ01XX",{"$nulls":3},"其他抗菌药"]
[{"$nulls":5},"乙",72,"康替唑胺片","*；","*","本品适用于治疗由对本品敏感的金黄色葡萄球菌（甲氧西林敏感和耐药的菌株）、化脓性链球菌或无乳链球菌引起的复杂性皮肤和软组织感染。\n为减少细菌耐药的发生，确保康替唑胺及其他抗菌药物的疗效，本品应仅用于治疗已确诊或高度怀疑由敏感菌引起的感染。本品不适用于治疗革兰阴性菌感染。如确诊或怀疑合并有革兰阴性菌感染，建议联合应用抗革兰阴性菌药物进行治疗。\n在选择或调整抗菌药物治疗方案时，应考虑进行细菌培养和药敏试验以分离并鉴定感染病原菌，确定其对本品的敏感性。如果没有这些试验的药敏数据做参考，则应根据当地细菌耐药性和抗菌药物敏感性等流行病学情况进行经验性治疗。在获得以上药敏结果之前可以先使用本品进行治疗，获得药敏结果后再选择进行针对性的病原治疗。","否","是"]
["XJ02",null,"全身用抗真菌药"]
["XJ02A",null,null,"全身用抗真菌药"]
["XJ02AA",{"$nulls":3},"抗生素类"]
[{"$nulls":5},"乙",73,"注射用两性霉素B胆固醇硫酸酯复合物","396元（50mg/支）","396元（50mg/支）","本品适用于患有深部真菌感染的患者；因肾损伤或药物毒性而不能使用有效剂量的两性霉素B的患者，或已经接受过两性霉素B治疗无效的患者均可使用。","否"]
["XJ02AC",{"$nulls":3},"三唑类衍生物"]
[{"$nulls":5},"乙",74,"泊沙康唑口服混悬液","*；","*","限以下情况方可支付：1.预防移植后（干细胞及实体器官移植）及恶性肿瘤患者有重度粒细胞缺乏的侵袭性曲霉菌和念球菌感染。2.伊曲康唑或氟康唑难治性口咽念珠菌病。3.接合菌纲类感染。","否","是"]
["XJ04",null,"抗分枝杆菌药"]
["XJ04A",null,null,"治疗结核病药"]
["XJ04AK",{"$nulls":3},"其他治疗结核病药"]
[{"$nulls":5},"乙",75,"富马酸贝达喹啉片","*；","*","限耐多药结核患者。","是","是"]
[{"$nulls":5},"乙",76,"德拉马尼片","*；","*","限耐多药结核患者。","是","是"]
["XJ05",null,"全身用抗病毒药"]
["XJ05A",null,null,"直接作用的抗病毒药"]
["XJ05AF",{"$nulls":3},"核苷及核苷酸逆转录酶抑制剂"]
[{"$nulls":5},"乙",77,"艾米替诺福韦片","*；","*","本品适用于慢性乙型肝炎成人患者的治疗。","是","是"]
[{"$nulls":5},"乙",78,"恩替卡韦口服溶液","43.3元（0.005%(210ml:10.5mg)/瓶）","43.3元（0.005%(210ml:10.5mg)/瓶）","恩替卡韦适用于病毒复制活跃，血清丙氨酸氨基转移酶（ALT）持续升高或肝脏组织学显示有活动性病变的慢性成人乙型肝炎的治疗（包括代偿及失代偿期肝病患者）。也适用于治疗2岁至<18岁慢性HBV感染代偿性肝病的核苷初治儿童患者，有病毒复制活跃和血清ALT水平持续升高的证据或中度至重度炎症和/或纤维化的组织学证据。","是"]
["XJ05AP",{"$nulls":3},"用于治疗HCV感染的抗病毒药物"]
[{"$nulls":5},"乙",79,"艾尔巴韦格拉瑞韦片","*；","*","本品用于治疗成人慢性丙型肝炎（CHC）感染。","是","是"]
[{"$nulls":5},"乙",80,"来迪派韦索磷布韦片","*；","*","本品适用于治疗成人和12至<18岁青少年的慢性丙型肝炎病毒(HCV)感染。","是","是"]
[{"$nulls":5},"乙",81,"索磷布韦维帕他韦片","*；","*","本品用于治疗成人慢性丙型肝炎病毒（HCV）感染。","是","是"]
[{"$nulls":5},"乙",82,"盐酸可洛派韦胶囊","119.5元(60mg/粒)(协议有效期内，谈判企业负责向购买盐酸可洛派韦胶囊的患者免费提供同疗程的索磷布韦片)","119.5元(60mg/粒)(协议有效期内，谈判企业负责向购买盐酸可洛派韦胶囊的患者免费提供同疗程的索磷布韦片)","限经HCV基因分型检测确诊为基因1b型以外的慢性丙型肝炎患者。","是"]
[{"$nulls":5},"乙",83,"索磷维伏片","*；","*","本品适用于治疗既往接受过含直接抗病毒药物（DAA）方案、无肝硬化或伴代偿性肝硬化（Child-Pugh A）的成人慢性丙型肝炎病毒（HCV）感染。","是","是"]
[{"$nulls":5},"乙",84,"达诺瑞韦钠片","8.3元（100mg/片）(协议有效期内，谈判企业负责向购买达诺瑞韦钠片的患者免费提供同疗程和相应剂量的利托那韦和利巴韦林，详见说明书)","8.3元（100mg/片）(协议有效期内，谈判企业负责向购买达诺瑞韦钠片的患者免费提供同疗程和相应剂量的利托那韦和利巴韦林，详见说明书)","与盐酸拉维达韦片等联合用于治疗初治的非肝硬化的基因1b型慢性丙型肝炎成人患者（用法用量详见盐酸拉维达韦片说明书）。","是"]
[{"$nulls":5},"乙",85,"盐酸拉维达韦片","51.12元（0.2g/片）(协议有效期内，谈判企业负责向购买盐酸拉维达韦片的患者免费提供同疗程和相应剂量的利托那韦和利巴韦林，详见说明书)","51.12元（0.2g/片）(协议有效期内，谈判企业负责向购买盐酸拉维达韦片的患者免费提供同疗程和相应剂量的利托那韦和利巴韦林，详见说明书)","盐酸拉维达韦片联合利托那韦强化的达诺瑞韦钠片和利巴韦林，用于治疗初治的基因lb型慢性丙型肝炎病毒感染的非肝硬化成人患者。盐酸拉维达韦片不得作为单药治疗。","是"]
[{"$nulls":5},"乙",86,"磷酸依米他韦胶囊","*；","*","磷酸依米他韦胶囊需与索磷布韦片联合，用于治疗成人基因1型非肝硬化慢性丙型肝炎。磷酸依米他韦胶囊不得作为单药治疗。","是","是"]
["XJ05AR",{"$nulls":3},"艾滋病毒感染的抗病毒药物"]
[{"$nulls":5},"乙",87,"艾考恩丙替片","*；","*","适用于治疗人类免疫缺陷病毒-1（HIV-1）感染的且无任何与整合酶抑制剂类药物、恩曲他滨或替诺福韦耐药性相关的已知突变的成人和青少年（年龄12岁及以上且体重至少为35kg）。","是","是"]
[{"$nulls":5},"乙",88,"奈韦拉平齐多拉米双夫定片","12.1元(每片含奈韦拉平0.2g, 齐多夫定0.3g和拉米夫定0.15g)","12.1元(每片含奈韦拉平0.2g, 齐多夫定0.3g和拉米夫定0.15g)","限艾滋病病毒感染。","是"]
[{"$nulls":5},"乙",89,"注射用艾博韦泰","532元(160mg/支)","532元(160mg/支)","限艾滋病病毒感染。","是"]
[{"$nulls":5},"乙",90,"比克恩丙诺片","*；","*","本品适用于作为完整方案治疗人类免疫缺陷病毒1型（HIV-1）感染的成人，且患者目前和既往无对整合酶抑制剂类药物、恩曲他滨或替诺福韦产生病毒耐药性的证据。","是","是"]
[{"$nulls":5},"乙",91,"艾诺韦林片","8.58元（75mg/片）","8.58元（75mg/片）","本品适用于与核苷类抗逆转录病毒药物联合使用，治疗成人HIV-1感染初治患者。","是"]
[{"$nulls":5},"乙",92,"拉米夫定多替拉韦片","*；","*","作为完整治疗方案用于无抗逆转录病毒治疗史，且对本品任一成分无已知耐药相关突变的1型人类免疫缺陷病毒（HIV-1）感染成人患者。","是","是"]
["XJ05AX",{"$nulls":3},"其他抗病毒药"]
[{"$nulls":5},"乙",93,"重组细胞因子基因衍生蛋白注射液","325元(10μg/瓶)","325元(10μg/瓶)","限HBeAg阳性的慢性乙型肝炎患者。","是"]
[{"$nulls":5},"乙",94,"盐酸阿比多尔颗粒","3元(0.1g/袋)","3元(0.1g/袋)","限流感重症高危人群及重症患者的抗流感病毒治疗。","否"]
[{"$nulls":5},"乙",95,"法维拉韦片(又称:法匹拉韦片)","3.69元(0.2g/片)","3.69元(0.2g/片)","限流感重症高危人群及重症患者的抗流感病毒治疗。","否"]
[{"$nulls":5},"乙",96,"玛巴洛沙韦片","*；","*","本品适用于12周岁及以上单纯性甲型和乙型流感患者，包括既往健康的患者以及存在流感并发症高风险的患者。","否","是"]
["XL","抗肿瘤药及免疫调节剂"]
["XL01",null,"抗肿瘤药"]
["XL01B",null,null,"抗代谢药"]
["XL01BC",{"$nulls":3},"嘧啶类似物"]
[{"$nulls":5},"乙",97,"注射用紫杉醇脂质体","*；","*","限1.卵巢癌的一线化疗及以后卵巢转移性癌的治疗、作为一线化疗，也可与顺铂联合应用；2.用于曾用过含阿霉素标准化疗的乳腺癌患者的后续治疗或复发患者的治疗。3.可与顺铂联合用于不能手术或放疗的非小细胞肺癌患者的一线化疗。","是","是"]
["XL01X",null,null,"其他抗肿瘤药"]
["XL01XC",{"$nulls":3},"单克隆抗体"]
[{"$nulls":5},"乙",98,"西妥昔单抗注射液","*；","*","1.本品用于治疗RAS基因野生型的转移性结直肠癌：与FOLFOX或FOLFIRI方案联合用于一线治疗；与伊立替康联合用于经含伊立替康治疗失败后的患者。2.本品用于治疗头颈部鳞状细胞癌：与铂类和氟尿嘧啶化疗联合用于一线治疗复发和/或转移性疾病。","是","是"]
[{"$nulls":5},"乙",99,"尼妥珠单抗注射液","1435元(50mg/瓶)","1435元(50mg/瓶)","限与放疗联合治疗表皮生长因子受体（EGFR）表达阳性的III/IV期鼻咽癌。","是"]
[{"$nulls":5},"乙",100,"注射用伊尼妥单抗","*；","*","限HER2阳性的转移性乳腺癌：与长春瑞滨联合治疗已接受过1个或多个化疗方案的转移性乳腺癌患者。","是","是"]
[{"$nulls":5},"乙",101,"帕妥珠单抗注射液","*；","*","限以下情况方可支付，且支付不超过12个月：1.HER2阳性的局部晚期、炎性或早期乳腺癌患者的新辅助治疗。2.具有高复发风险HER2阳性早期乳腺癌患者的辅助治疗。","是","是"]
[{"$nulls":5},"乙",102,"信迪利单抗注射液","*；","*","1.本品适用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤的治疗。本适应症是基于一项单臂临床试验的客观缓解率和缓解持续时间结果给予的有条件批准。本适应症的完全批准将取决于正在开展中的确证性随机对照临床试验能否证实信迪利单抗治疗相对于标准治疗的显著临床获益。2.信迪利单抗联合培美曲塞和铂类化疗，用于未经系统治疗的表皮生长因子受体（EGFR）基因突变阴性和间变性淋巴瘤激酶（ALK）阴性的晚期或复发性非鳞状细胞非小细胞肺癌的治疗。3.信迪利单抗联合吉西他滨和铂类化疗，用于不可手术切除的晚期或复发性鳞状细胞非小细胞肺癌的一线治疗。4.信迪利单抗联合贝伐珠单抗，用于既往未接受过系统治疗的不可切除或转移性肝细胞癌的一线治疗。","是","是"]
[{"$nulls":5},"乙",103,"替雷利珠单抗注射液","*；","*","1.经典型霍奇金淋巴瘤：本品适用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤的治疗。本适应症是基于一项单臂临床试验的客观缓解率和缓解持续时间结果给予的附条件批准。本适应症的完全批准将取决于正在开展中的确证性随机对照临床试验能否证实本品治疗相对于标准治疗的显著临床获益。2.尿路上皮癌：本品适用于PD-L1高表达的含铂化疗失败包括新辅助或辅助化疗12个月内进展的局部晚期或转移性尿路上皮癌的治疗。本适应症是基于一项单臂临床试验的客观缓解率和缓解持续时间结果给予的附条件批准。本适应症的完全批准将取决于正在开展中的确证性随机对照临床试验能否证实本品治疗相对于标准治疗的显著临床获益。3.非小细胞肺癌：本品联合紫杉醇和卡铂用于不可手术切除的局部晚期或转移性鳞状非小细胞肺癌的一线治疗。本品联合培美曲塞和铂类化疗用于表皮生长因子受体（EGFR）基因突变阴性和间变性淋巴瘤激酶（ALK）阴性、不可手术切除的局部晚期或转移性非鳞状非小细胞肺癌的一线治疗。4.肝细胞癌：本品适用于至少经过一种全身治疗的肝细胞癌（HCC）的治疗。本适应症是基于一项II期临床试验的客观缓解率和总生存期结果给予的附条件批准。本适应症的完全批准将取决于正在开展中的确证性随机对照临床试验能否证实本品治疗相对于标准治疗的显著临床获益。","是","是"]
[{"$nulls":5},"乙",104,"特瑞普利单抗注射液","*；\n","*","1.本品适用于既往接受全身系统治疗失败的不可切除或转移性黑色素瘤的治疗。* 2.本品适用于既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌患者的治疗。* 3.本品适用于含铂化疗失败包括新辅助或辅助化疗12个月内进展的局部晚期或转移性尿路上皮癌的治疗。* \n*以上适应症在中国是基于单臂临床试验的客观缓解率结果给予的附条件批准。本适应症的完全批准将取决于正在开展中的确证性临床试验能否证实中国患者的长期临床获益。","是","是"]
[{"$nulls":5},"乙",105,"注射用卡瑞利珠单抗","*；","*","限：1.至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。2.既往接受过索拉非尼治疗和/或含奥沙利铂系统化疗的晚期肝细胞癌患者的治疗。3.联合培美曲塞和卡铂适用于表皮生长因子受体（EGFR）基因突变阴性和间变性淋巴瘤激酶（ALK）阴性的、不可手术切除的局部晚期或转移性非鳞状非小细胞肺癌（NSCLC）的一线治疗。4.既往接受过一线化疗后疾病进展或不可耐受的局部晚期或转移性食管鳞癌患者的治疗。","是","是"]
[{"$nulls":5},"乙",106,"奥妥珠单抗注射液","*；","*","本品与化疗联合，用于初治的II期伴有巨大肿块、III期或IV期滤泡性淋巴瘤成人患者，达到至少部分缓解的患者随后用奥妥珠单抗维持治疗。","是","是"]
[{"$nulls":5},"乙",107,"达雷妥尤单抗注射液","*；\n","*","本品适用于：1.与来那度胺和地塞米松联合用药或与硼替佐米和地塞米松联合用药治疗既往至少接受过一线治疗的多发性骨髓瘤成年患者。2.单药治疗复发和难治性多发性骨髓瘤成年患者，患者既往接受过包括蛋白酶体抑制剂和免疫调节剂的治疗且最后一次治疗时出现疾病进展。","是","是"]
["XL01XE",{"$nulls":3},"蛋白激酶抑制剂"]
[{"$nulls":5},"乙",108,"甲磺酸氟马替尼片","65元(0.2g/片)；\n38.24元(0.1g/片)","65元(0.2g/片)；\n38.24元(0.1g/片)","限费城染色体阳性的慢性髓性白血病（Ph+ CML）慢性期成人患者。","是"]
[{"$nulls":5},"乙",109,"甲磺酸奥希替尼片","*；\n","*","限表皮生长因子受体（EGFR）外显子19缺失或外显子21（L858R）置换突变的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者的一线治疗；既往因表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗时或治疗后出现疾病进展，并且经检验确认存在EGFR T790M 突变阳性的局部晚期或转移性非小细胞肺癌成人患者的治疗。","是","是"]
[{"$nulls":5},"乙",110,"甲磺酸阿美替尼片","176元(55mg/片)","176元(55mg/片)","限既往因表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗时或治疗后出现疾病进展，并且经检验确认存在EGFR T790M 突变阳性的局部晚期或转移性非小细胞肺癌成人患者。","是"]
[{"$nulls":5},"乙",111,"盐酸安罗替尼胶囊","*；","*","1.用于既往至少接受过2种系统化疗后出现进展或复发的局部晚期或转移性非小细胞肺癌患者的治疗。对于存在表皮生长因子受体（EGFR）基因突变或间变性淋巴瘤激酶（ALK）阳性的患者，在开始本品治疗前应接受相应的标准靶向药物治疗后进展、且至少接受过2种系统化疗后出现进展或复发。2.用于腺泡状软组织肉瘤、透明细胞肉瘤以及既往至少接受过含蒽环类化疗方案治疗后进展或复发的其他晚期软组织肉瘤患者的治疗。3.用于既往至少接受过2种化疗方案治疗后进展或复发的小细胞肺癌患者的治疗。该适应症是基于一项包括119例既往至少接受过2种化疗方案治疗后进展或复发的小细胞肺癌患者的II期临床试验的结果给予的附条件批准。该适应症的完全批准将取决于正在进行的确证性试验证实本品在该人群的临床获益。4.用于具有临床症状或明确疾病进展的、不可切除的局部晚期或转移性甲状腺髓样癌患者的治疗。该适应症是基于一项包括91例晚期甲状腺髓样癌的IIB期临床试验结果给予的附条件批准。该适应症的完全批准将取决于正在进行的确证性试验证实本品在该人群的临床获益。","是","是"]
[{"$nulls":5},"乙",112,"克唑替尼胶囊","*；","*","限间变性淋巴瘤激酶（ALK）阳性的局部晚期或转移性非小细胞肺癌患者或 ROS1阳性的晚期非小细胞肺癌患者。","是","是"]
[{"$nulls":5},"乙",113,"塞瑞替尼胶囊","*；","*","限间变性淋巴瘤激酶（ALK）阳性的局部晚期或转移性非小细胞肺癌（NSCLC）患者的治疗。","是","是"]
[{"$nulls":5},"乙",114,"盐酸阿来替尼胶囊","*；","*","限间变性淋巴瘤激酶（ALK）阳性的局部晚期或转移性非小细胞肺癌患者。","是","是"]
[{"$nulls":5},"乙",115,"培唑帕尼片","160元(200mg/片)；\n272元(400mg/片)","160元(200mg/片)；\n272元(400mg/片)","限晚期肾细胞癌患者的一线治疗和曾经接受过细胞因子治疗的晚期肾细胞癌的治疗。","是"]
[{"$nulls":5},"乙",116,"阿昔替尼片","*；","*","限既往接受过一种酪氨酸激酶抑制剂或细胞因子治疗失败的进展期肾细胞癌(RCC)的成人患者。","是","是"]
[{"$nulls":5},"乙",117,"瑞戈非尼片","*；","*","1.肝细胞癌二线治疗；2.转移性结直肠癌三线治疗；3.胃肠道间质瘤三线治疗。","是","是"]
[{"$nulls":5},"乙",118,"甲磺酸阿帕替尼片","*；","*","1.本品单药用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。2.本品单药用于既往接受过至少一线系统性治疗后失败或不可耐受的晚期肝细胞癌患者。","是","是"]
[{"$nulls":5},"乙",119,"呋喹替尼胶囊","*；","*","限转移性结直肠癌患者的三线治疗。","是","是"]
[{"$nulls":5},"乙",120,"马来酸吡咯替尼片","*；","*","限表皮生长因子受体2（HER2）阳性的复发或转移性乳腺癌患者的二线治疗。","是","是"]
[{"$nulls":5},"乙",121,"尼洛替尼胶囊","*；","*","1.用于治疗新诊断的费城染色体阳性的慢性髓性白血病（Ph+CML）慢性期成人患者及2岁以上的儿童患者；2.用于对既往治疗（包括伊马替尼）耐药或不耐受的费城染色体阳性的慢性髓性白血病（Ph+CML）慢性期或加速期成人患者以及慢性期2岁以上的儿童患者。","是","是"]
[{"$nulls":5},"乙",122,"伊布替尼胶囊","*；","*","限1.既往至少接受过一种治疗的套细胞淋巴瘤（MCL）患者的治疗；2.慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）患者的治疗；3.华氏巨球蛋白血症患者的治疗，按说明书用药。","是","是"]
[{"$nulls":5},"乙",123,"泽布替尼胶囊","*；","*","1.既往至少接受过一种治疗的成人套细胞淋巴瘤（MCL）患者。2.既往至少接受过一种治疗的成人慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）患者。分别基于一项单臂临床试验的客观缓解率结果附条件批准上述适应症，完全批准将取决于正在开展中的确证性随机对照临床试验结果。3.既往至少接受过一种治疗的成人华氏巨球蛋白血症（WM）患者。基于一项单臂临床试验的主要缓解率结果附条件批准上述适应症，完全批准将取决于正在开展中的确证性随机对照临床试验结果。","是","是"]
[{"$nulls":5},"乙",124,"磷酸芦可替尼片","*；","*","限中危或高危的原发性骨髓纤维化（PMF）、真性红细胞增多症继发的骨髓纤维化（PPV-MF）或原发性血小板增多症继发的骨髓纤维化（PET-MF）的患者。","是","是"]
[{"$nulls":5},"乙",125,"维莫非尼片","*；","*","治疗经CFDA批准的检测方法确定的BRAF V600 突变阳性的不可切除或转移性黑色素瘤。","是","是"]
[{"$nulls":5},"乙",126,"曲美替尼片","*；","*","限1.BRAF V600 突变阳性不可切除或转移性黑色素瘤：联合甲磺酸达拉非尼适用于治疗BRAF V600 突变阳性的不可切除或转移性黑色素瘤患者。2.BRAF V600 突变阳性黑色素瘤的术后辅助治疗：联合甲磺酸达拉非尼适用于BRAF V600 突变阳性的III期黑色素瘤患者完全切除后的辅助治疗。","是","是"]
[{"$nulls":5},"乙",127,"甲磺酸达拉非尼胶囊","*；","*","限1.BRAF V600 突变阳性不可切除或转移性黑色素瘤：联合曲美替尼适用于治疗BRAF V600 突变阳性的不可切除或转移性黑色素瘤患者。2.BRAF V600 突变阳性黑色素瘤的术后辅助治疗：联合曲美替尼适用于BRAF V600 突变阳性的III期黑色素瘤患者完全切除后的辅助治疗。","是","是"]
[{"$nulls":5},"乙",128,"甲磺酸仑伐替尼胶囊","*；","*","限既往未接受过全身系统治疗的不可切除的肝细胞癌患者。","是","是"]
[{"$nulls":5},"乙",129,"甲苯磺酸多纳非尼片","*；","*","本品用于既往未接受过全身系统性治疗的不可切除肝细胞癌患者。","是","是"]
[{"$nulls":5},"乙",130,"盐酸恩沙替尼胶囊","*；","*","适用于此前接受过克唑替尼治疗后进展的或者对克唑替尼不耐受的间变性淋巴瘤激酶（ALK）阳性的局部晚期或转移性非小细胞肺癌（NSCLC）患者的治疗。","是","是"]
[{"$nulls":5},"乙",131,"甲磺酸伏美替尼片","*；","*","本品用于既往经表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)治疗时或治疗后出现疾病进展，并且经检测确认存在EGFR T790M突变阳性的局部晚期或转移性非小细胞性肺癌(NSCLC)成人患者的治疗。该适应症是基于一项包括220例不可手术切除的局部晚期或转移性、经第一/第二代EGFR TKI治疗进展并伴有EGFR T790M突变阳性、或原发性EGFR T790M突变阳性NSCLC患者的IIb期临床试验的结果给予的附条件批准。该适应症的完全批准将取决于正在进行的确证性随机对照试验证实本品的临床获益。","是","是"]
[{"$nulls":5},"乙",132,"达可替尼片","*；\n","*","单药用于表皮生长因子受体（EGFR）19号外显子缺失突变或21号外显子L858R置换突变的局部晚期或转移性非小细胞肺癌（NSCLC）患者的一线治疗。","是","是"]
[{"$nulls":5},"乙",133,"奥布替尼片","*；","*","本品适用于治疗：1.既往至少接受过一种治疗的成人套细胞淋巴瘤（MCL）患者。2.既往至少接受过一种治疗的成人慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）患者。上述适应症分别基于一项单臂临床试验的客观缓解率结果给予的附条件批准。本品的完全批准将取决于正在开展中的确证性随机对照临床试验结果。","是","是"]
[{"$nulls":5},"乙",134,"阿贝西利片","*；","*","本品适用于激素受体（HR）阳性、人表皮生长因子受体2（HER2）阴性的局部晚期或转移性乳腺癌：1.与芳香化酶抑制剂联合使用作为绝经后女性患者的初始内分泌治疗；2.与氟维司群联合用于既往曾接受内分泌治疗后出现疾病进展的患者。","是","是"]
[{"$nulls":5},"乙",135,"马来酸奈拉替尼片","*；","*","适用于人类表皮生长因子受体2（HER2）阳性的早期乳腺癌成年患者，在接受含曲妥珠单抗辅助治疗之后的强化辅助治疗。","是","是"]
[{"$nulls":5},"乙",136,"索凡替尼胶囊","*；\n","*","本品单药适用于无法手术切除的局部晚期或转移性、进展期非功能性、分化良好（G1、G2）的胰腺和非胰腺来源的神经内分泌瘤。","是","是"]
[{"$nulls":5},"乙",137,"盐酸埃克替尼片","*；","*","1.本品单药适用于治疗表皮生长因子受体（EGFR)基因具有敏感突变的局部晚期或转移性非小细胞肺癌（NSCLC）患者的一线治疗。2.本品单药可适用于治疗既往接受过至少一个化疗方案失败后的局部晚期或转移性非小细胞肺癌（NSCLC），既往化疗主要是指以铂类为基础的联合化疗。3.本品单药适用于II-IIIA期伴有表皮生长因子受体（EGFR）基因敏感突变非小细胞肺癌（NSCLC）术后辅助治疗。4.不推荐本品用于EGFR野生型非小细胞肺癌患者。","是","是"]
["XL01XX",{"$nulls":3},"其他抗肿瘤药"]
[{"$nulls":5},"乙",138,"枸橼酸伊沙佐米胶囊","*；","*","1.每2个疗程需提供治疗有效的证据后方可继续支付；2.由三级医院血液专科或血液专科医院医师处方；3.与来那度胺联合使用时，只支付伊沙佐米或来那度胺中的一种。","是","是"]
[{"$nulls":5},"乙",139,"培门冬酶注射液","1477.7元(2ml:1500IU/支)；\n2980元(5ml:3750IU/支)","1477.7元(2ml:1500IU/支)；\n2980元(5ml:3750IU/支)","儿童急性淋巴细胞白血病患者的一线治疗。","是"]
[{"$nulls":5},"乙",140,"重组人血管内皮抑制素注射液","490元(15mg/3ml/支)","490元(15mg/3ml/支)","限晚期非小细胞肺癌患者。","是"]
[{"$nulls":5},"乙",141,"西达本胺片","343元(5mg/片)","343元(5mg/片)","限既往至少接受过1次全身化疗的复发或难治的外周T细胞淋巴瘤（PTCL）患者。","是"]
[{"$nulls":5},"乙",142,"奥拉帕利片","*；","*","限携带胚系或体细胞BRCA突变的（gBRCAm或sBRCAm）晚期上皮性卵巢癌、输卵管癌或原发性腹膜癌初治成人患者在一线含铂化疗达到完全缓解或部分缓解后的维持治疗；铂敏感的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌患者。","是","是"]
[{"$nulls":5},"乙",143,"甲苯磺酸尼拉帕利胶囊","*；","*","1.本品适用于晚期上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者对一线含铂化疗达到完全缓解或部分缓解后的维持治疗。2.本品适用于铂敏感的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者在含铂化疗达到完全缓解或部分缓解后的维持治疗。","是","是"]
[{"$nulls":5},"乙",144,"氟唑帕利胶囊","*；","*","1.用于既往经过二线及以上化疗的伴有胚系BRCA突变(gBRCAm)的铂敏感复发性卵巢癌、输卵管癌或原发性腹膜癌患者的治疗。2.用于铂敏感的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者在含铂化疗达到完全缓解或部分缓解后的维持治疗。","是","是"]
[{"$nulls":5},"乙",145,"帕米帕利胶囊","*；","*","用于既往经过二线及以上化疗的伴有胚系BRCA（gBRCA）突变的复发性晚期卵巢癌、输卵管癌或原发性腹膜癌患者的治疗。该适应症是基于一项包括113例既往经过二线及以上化疗的伴有gBRCA突变的复发性晚期卵巢癌、输卵管癌或原发性腹膜癌患者中开展的开放性、多中心、单臂、II期临床试验结果给予的附条件批准。该适应症的完全批准将取决于正在进行的确证性试验证实本品在该人群的临床获益。","是","是"]
[{"$nulls":5},"乙",146,"甲磺酸艾立布林注射液","*；","*","本品适用于既往接受过至少两种化疗方案的局部晚期或转移性乳腺癌患者。既往的化疗方案应包含一种蒽环类和一种紫杉烷类药物。","是","是"]
[{"$nulls":5},"乙",147,"注射用维迪西妥单抗","*；","*","本品适用于至少接受过2个系统化疗的HER2过表达局部晚期或转移性胃癌（包括胃食管结合部腺癌）的患者，HER2过表达定义为HER2免疫组织化学检查结果为2+或3+。该适应症是基于一项HER2过表达的局部晚期或转移性胃癌患者（包括胃食管结合部腺癌）的II期单臂临床试验结果给予的附条件批准。该适应症的完全获批将取决于正在开展中的确证性随机对照临床试验能否证实本品在该人群的临床获益。","是","是"]
["XL02",null,"内分泌治疗用药"]
["XL02A",null,null,"激素类及相关药物"]
[{"$nulls":5},"乙",148,"醋酸戈舍瑞林缓释植入剂","*；","*",null,"是","是"]
["XL02B",null,null,"激素拮抗剂及相关药物"]
["XL02BB",{"$nulls":3},"抗雄激素"]
[{"$nulls":5},"乙",149,"恩扎卢胺软胶囊","*；","*","限雄激素剥夺治疗（ADT）失败后无症状或有轻微症状且未接受化疗的转移性去势抵抗性前列腺癌（CRPC）成年患者的治疗。","是","是"]
[{"$nulls":5},"乙",150,"阿帕他胺片","*；","*","1.转移性内分泌治疗敏感性前列腺癌（mHSPC）成年患者。2.有高危转移风险的非转移性去势抵抗性前列腺癌（NM-CRPC）成年患者。","是","是"]
[{"$nulls":5},"乙",151,"达罗他胺片","*；","*","适用于治疗有高危转移风险的非转移性去势抵抗性前列腺癌（NM-CRPC）成年患者。","是","是"]
["XL03",null,"免疫兴奋剂"]
["XL03A",null,null,"免疫兴奋剂"]
["XL03AA",{"$nulls":3},"集落刺激因子"]
[{"$nulls":5},"乙",152,"硫培非格司亭注射液","*；","*","限前次化疗曾发生重度中性粒细胞减少合并发热的患者。","否","是"]
["XL04",null,"免疫抑制剂"]
["XL04A",null,null,"免疫抑制剂"]
["XL04AA",{"$nulls":3},"选择性免疫抑制剂"]
[{"$nulls":5},"乙",153,"特立氟胺片","*；","*","限常规治疗无效的多发性硬化患者。","是","是"]
[{"$nulls":5},"乙",154,"西尼莫德片","*；","*","限成人复发型多发性硬化的患者。","是","是"]
[{"$nulls":5},"乙",155,"盐酸芬戈莫德胶囊","*；","*","限10岁及以上患者复发型多发性硬化（RMS）的患者。","是","是"]
[{"$nulls":5},"乙",156,"依维莫司片","*；","*","限以下情况方可支付：1.接受舒尼替尼或索拉非尼治疗失败的晚期肾细胞癌成人患者。2.不可切除的、局部晚期或转移性的、分化良好的（中度分化或高度分化）进展期胰腺神经内分泌瘤成人患者。3.无法手术切除的、局部晚期或转移性的、分化良好的、进展期非功能性胃肠道或肺源神经内分泌肿瘤患者。4.不需立即手术治疗的结节性硬化症相关的肾血管平滑肌脂肪瘤（TSC-AML)成人患者。5.不能手术的结节性硬化症相关的室管膜下巨细胞星型细胞瘤的患者。","是","是"]
[{"$nulls":5},"乙",157,"巴瑞替尼片","*；","*","限诊断明确的类风湿关节炎经传统DMARDs治疗3-6个月疾病活动度下降低于50%者，并需风湿病专科医师处方。","否","是"]
[{"$nulls":5},"乙",158,"注射用贝利尤单抗","*；","*","本品与常规治疗联合，适用于在常规治疗基础上仍具有高疾病活动（例如：抗dsDNA抗体阳性及低补体、SELENA-SLEDAI评分≥8）的活动性、自身抗体阳性的系统性红斑狼疮（SLE）5岁及以上患者。","是","是"]
[{"$nulls":5},"乙",159,"注射用泰它西普","*；","*","本品与常规治疗联合，适用于在常规治疗基础上仍具有高疾病活动（例如：抗ds-DNA抗体阳性及低补体、SELENA-SLEDAI评分≥8）的活动性、自身抗体阳性的系统性红斑狼疮（SLE）成年患者。该适应症是基于一项接受常规治疗仍具有高疾病活动的系统性红斑狼疮成年患者的II期临床试验结果给予的附条件批准。本适应症的完全获批将取决于确证性随机对照临床试验能否证实本品在该患者人群的临床获益。","是","是"]
["XL04AB",{"$nulls":3},"肿瘤坏死因子α（TNF-α）抑制剂"]
[{"$nulls":5},"乙",160,"注射用英夫利西单抗","*；","*","限以下情况方可支付：1.诊断明确的类风湿关节炎经传统DMARDs治疗3-6个月疾病活动度下降低于50%者；诊断明确的强直性脊柱炎（不含放射学前期中轴性脊柱关节炎）NSAIDs充分治疗3个月疾病活动度下降低于50%者；并需风湿病专科医师处方。2.对系统性治疗无效、禁忌或不耐受的重度斑块状银屑病患者，需按说明书用药。3.克罗恩病患者的二线治疗。4.中重度溃疡性结肠炎患者的二线治疗。","是","是"]
[{"$nulls":5},"乙",161,"依那西普注射液","*；","*","限诊断明确的类风湿关节炎经传统DMARDs治疗3-6个月疾病活动度下降低于50%者；诊断明确的强直性脊柱炎（不含放射学前期中轴性脊柱关节炎）NSAIDs充分治疗3个月疾病活动度下降低于50%者；并需风湿病专科医师处方。","否","是"]
["XL04AC",{"$nulls":3},"白介素抑制剂"]
[{"$nulls":5},"乙",162,"司库奇尤单抗注射液","*；","*","限以下情况方可支付：1.诊断明确的强直性脊柱炎（不含放射学前期中轴性脊柱关节炎）NSAIDs充分治疗3个月疾病活动度下降低于50%者；并需风湿病专科医师处方。2.对传统治疗无效、有禁忌或不耐受的中重度斑块状银屑病患者，需按说明书用药。","是","是"]
[{"$nulls":5},"乙",163,"乌司奴单抗注射液","*；","*","1.斑块状银屑病：本品适用于对环孢素、甲氨蝶呤（MTX）或PUVA（补骨脂素和紫外线A）等其他系统性治疗不应答、有禁忌或无法耐受的成年中重度斑块状银屑病患者。2.克罗恩病：本品适用于对传统治疗或肿瘤坏死因子α（TNF-α）拮抗剂应答不足、失应答或无法耐受的成年中重度活动性克罗恩病患者。","是","是"]
[{"$nulls":5},"乙",164,"乌司奴单抗注射液(静脉输注)","*；","*","本品适用于对传统治疗或肿瘤坏死因子α（TNF-α）拮抗剂应答不足、失应答或无法耐受的成年中重度活动性克罗恩病患者。","是","是"]
[{"$nulls":5},"乙",165,"依奇珠单抗注射液","*；","*","本品用于治疗适合系统治疗或光疗的中度至重度斑块型银屑病成人患者。","是","是"]
["XL04AX",{"$nulls":3},"其他免疫抑制剂"]
[{"$nulls":5},"乙",166,"乙磺酸尼达尼布软胶囊","*；","*","限特发性肺纤维化（IPF）或系统性硬化病相关间质性肺疾病（SSc-ILD）患者。","是","是"]
[{"$nulls":5},"乙",167,"泊马度胺胶囊","*；","*","本品与地塞米松联用，适用于既往接受过至少两种治疗（包括来那度胺和一种蛋白酶体抑制剂），且在最后一次治疗期间或治疗结束后60天内发生疾病进展的成年多发性骨髓瘤患者。","是","是"]
["XM","肌肉-骨骼系统药物"]
["XM05",null,"治疗骨病的药物"]
["XM05B",null,null,"影响骨结构和矿化的药物"]
["XM05BX",{"$nulls":3},"其他影响骨结构和矿化的药物"]
[{"$nulls":5},"乙",168,"地舒单抗注射液","*；","*","限绝经后妇女的重度骨质疏松；限不可手术切除或者手术切除可能导致严重功能障碍的骨巨细胞瘤。","是","是"]
["XM09",null,"其他肌肉-骨骼系统疾病用药"]
[{"$nulls":5},"乙",169,"诺西那生钠注射液","*；","*","本品用于治疗5q脊髓性肌萎缩症。","是","是"]
["XN","神经系统药物"]
["XN01",null,"麻醉剂"]
["XN01A",null,null,"全身麻醉剂"]
["XN01AX",{"$nulls":3},"其他全身麻醉药"]
[{"$nulls":5},"乙",170,"盐酸艾司氯胺酮注射液","91.8元(2ml:50mg/支)","91.8元(2ml:50mg/支)","限用于与镇静麻醉药联合诱导和实施全身麻醉。","否"]
[{"$nulls":5},"乙",171,"环泊酚注射液","*；","*","本品适用于：消化道内镜检查中的镇静；全身麻醉诱导。","否","是"]
["XN01B",null,null,"局部麻醉剂"]
["XN01BB",{"$nulls":3},"酰胺类"]
[{"$nulls":5},"乙",172,"利多卡因凝胶贴膏","18.05元（700mg/片）","18.05元（700mg/片）","限带状疱疹患者。","否"]
["XN03",null,"抗癫痫药"]
["XN03A",null,null,"抗癫痫药"]
[{"$nulls":5},"乙",173,"吡仑帕奈片","*；","*",null,"否","是"]
["XN05",null,"精神安定药"]
["XN05A",null,null,"抗精神病药"]
["XN05AE",{"$nulls":3},"吲哚衍生物"]
[{"$nulls":5},"乙",174,"盐酸鲁拉西酮片","*；","*",null,"否","是"]
["XN05AX",{"$nulls":3},"其他抗精神病药"]
[{"$nulls":5},"乙",175,"注射用利培酮微球(II)","*；","*","用于治疗急性和慢性精神分裂症以及其它各种精神病性状态的明显的阳性症状和明显的阴性症状。可减轻与精神分裂症有关的情感症状。","是 ","是"]
[{"$nulls":5},"乙",176,"氘丁苯那嗪片","*；","*","限与亨廷顿病有关的舞蹈病或成人迟发性运动障碍。","是","是"]
[{"$nulls":5},"乙",177,"棕榈帕利哌酮酯注射液（3M）","*；","*","限接受过棕榈酸帕利哌酮注射液（1个月剂型）至少4个月充分治疗的精神分裂症患者。","是","是"]
[{"$nulls":5},"乙",178,"布南色林片","*；","*",null,"否","是"]
["XN05C",null,null,"催眠药和镇静药"]
[{"$nulls":5},"乙",179,"水合氯醛灌肠剂","17元(1.34g:0.5g/瓶)","17元(1.34g:0.5g/瓶)","限儿童。","否"]
[{"$nulls":5},"乙",180,"注射用甲苯磺酸瑞马唑仑","*；","*","本品适用于胃镜、结肠镜检查的镇静。","否","是"]
[{"$nulls":5},"乙",181,"注射用苯磺酸瑞马唑仑","*；","*","本品适用于结肠镜检查的镇静。","否","是"]
[{"$nulls":5},"乙",182,"水合氯醛/糖浆组合包装","25.11元（(水合氯醛浓缩液0.671g∶0.5g/糖浆4.5ml)/瓶）；\n42.68元（(水合氯醛浓缩液1.342g∶1g/糖浆9ml)/瓶）","25.11元（(水合氯醛浓缩液0.671g∶0.5g/糖浆4.5ml)/瓶）；\n42.68元（(水合氯醛浓缩液1.342g∶1g/糖浆9ml)/瓶）","儿童检查、操作前的镇静、催眠。","否"]
[{"$nulls":5},"乙",183,"咪达唑仑口服溶液","*；","*","用于儿童诊断或治疗性操作前以及操作过程中的镇静/抗焦虑/遗忘；也可用于儿童术前镇静/抗焦虑/遗忘。","否","是"]
["XN06",null,"精神兴奋药"]
["XN06D",null,null,"抗痴呆药"]
["XN06DX",{"$nulls":3},"其他抗痴呆药"]
[{"$nulls":5},"乙",184,"甘露特钠胶囊","*；","*","用于轻度至中度阿尔茨海默病，改善患者认知功能。","否","是"]
["XN07",null,"其他神经系统药物"]
["XN07X",null,null,"其他神经系统药物"]
[{"$nulls":5},"乙",185,"注射用尤瑞克林","*；","*","限新发的急性中度缺血性脑卒中患者，应在发作48小时内开始使用，支付不超过21天。","否","是"]
[{"$nulls":5},"乙",186,"依达拉奉氯化钠注射液","113.6元(100ml:依达拉奉30mg与氯化钠855mg/瓶)；\n113.6元(100ml:依达拉奉30mg与氯化钠855mg/袋)","113.6元(100ml:依达拉奉30mg与氯化钠855mg/瓶)；\n113.6元(100ml:依达拉奉30mg与氯化钠855mg/袋)","限肌萎缩侧索硬化（ALS）的患者。","是"]
[{"$nulls":5},"乙",187,"依达拉奉右莰醇注射用浓溶液","48.8元(5ml:依达拉奉10mg与右莰醇2.5mg/支)","48.8元(5ml:依达拉奉10mg与右莰醇2.5mg/支)","限新发的急性缺血性脑卒中患者在发作48小时内开始使用，支付不超过14天。","否"]
[{"$nulls":5},"乙",188,"丁苯酞软胶囊","3.36元(0.1g/粒)","3.36元(0.1g/粒)","限新发的急性缺血性脑卒中患者在发作72小时内开始使用，支付不超过20天。","否"]
[{"$nulls":5},"乙",189,"丁苯酞氯化钠注射液","139元(100ml:丁苯酞25mg与氯化钠0.9g/支)","139元(100ml:丁苯酞25mg与氯化钠0.9g/支)","限新发的急性缺血性脑卒中患者在发作48小时内开始使用，支付不超过14天。","否"]
[{"$nulls":5},"乙",190,"氨吡啶缓释片","*；","*","本品用于改善多发性硬化合并步行障碍（EDSS评分4-7分）的成年患者的步行能力。","是","是"]
[{"$nulls":5},"乙",191,"氯苯唑酸软胶囊",null,"*","本品适用于治疗成人野生型或遗传型转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM），以减少心血管死亡及心血管相关住院。","是","是"]
["XR","呼吸系统",{"$nulls":6},"*；"]
["XR01",null,"鼻部制剂"]
["XR01A",null,null,"减轻充血药及其他鼻局部用药"]
[{"$nulls":5},"乙",192,"苯环喹溴铵鼻喷雾剂","*；\n","*","本品适用于改善变应性鼻炎引起的流涕、鼻塞、鼻痒和喷嚏症状。","否","是"]
["XR03",null,"用于阻塞性气道疾病的药物"]
["XR03A",null,null,"吸入的肾上腺素能类药"]
[{"$nulls":5},"乙",193,"乌美溴铵维兰特罗吸入粉雾剂","*；","*","限中重度慢性阻塞性肺病。","否","是"]
[{"$nulls":5},"乙",194,"茚达特罗格隆溴铵吸入粉雾剂用胶囊（茚达特罗格隆溴铵吸入粉雾剂）","*；","*","限中重度慢性阻塞性肺病。","否","是"]
[{"$nulls":5},"乙",195,"格隆溴铵福莫特罗吸入气雾剂","*；","*","限中重度慢性阻塞性肺病。","否","是"]
[{"$nulls":5},"乙",196,"布地格福吸入气雾剂","*；","*","限中重度慢性阻塞性肺病。","否","是"]
[{"$nulls":5},"乙",197,"氟替美维吸入粉雾剂","*；","*","限中重度慢性阻塞性肺病。","否","是"]
[{"$nulls":5},"乙",198,"盐酸左沙丁胺醇雾化吸入溶液","8.46元(3ml:0.31mg/支)；\n14.56元(3ml:0.63mg/支)  ","8.46元(3ml:0.31mg/支)；\n14.56元(3ml:0.63mg/支)",null,"否"]
[{"$nulls":5},"乙",199,"盐酸丙卡特罗粉雾剂","68.9元(10μg/吸，200吸/支)","68.9元(10μg/吸，200吸/支)",null,"否"]
["XR03D",null,null,"治疗阻塞性气道疾病的其他全身用药物"]
[{"$nulls":5},"乙",200,"注射用奥马珠单抗","*；","*","限经吸入型糖皮质激素和长效吸入型β2-肾上腺素受体激动剂治疗后，仍不能有效控制症状的中至重度持续性过敏性哮喘患者，并需IgE（免疫球蛋白E）介导确诊证据。","是","是"]
["XS","感觉器官药物"]
["XS01",null,"眼科用药"]
["XS01E",null,null,"抗青光眼制剂和缩瞳剂"]
[{"$nulls":5},"乙",201,"他氟前列素滴眼液","14.76元（0.3ml:4.5μg/支）；\n74.8元（2.5ml:37.5μg/支）","14.76元（0.3ml:4.5μg/支）；\n74.8元（2.5ml:37.5μg/支）",null,"否"]
[{"$nulls":5},"乙",202,"布林佐胺噻吗洛尔滴眼液","*；","*","限二线用药。","否","是"]
[{"$nulls":5},"乙",203,"布林佐胺溴莫尼定滴眼液","*；","*","限二线用药。","否","是"]
["XS01L",null,null,"眼血管病用药"]
[{"$nulls":5},"乙",204,"地塞米松玻璃体内植入剂","*；","*","限视网膜静脉阻塞（RVO）的黄斑水肿患者，并应同时符合以下条件：1.需三级综合医院眼科或二级及以上眼科专科医院医师处方；2.首次处方时病眼基线矫正视力0.05-0.5；3.事前审查后方可用，初次申请需有血管造影或OCT（全身情况不允许的患者可以提供OCT血管成像）证据；4.每眼累计最多支付5支，每个年度最多支付2支。","是","是"]
[{"$nulls":5},"乙",205,"康柏西普眼用注射液","*；","*","限以下疾病：1.50岁以上的湿性年龄相关性黄斑变性（AMD）；2.糖尿病性黄斑水肿（DME）引起的视力损害；3.脉络膜新生血管（CNV）导致的视力损害。应同时符合以下条件：1.需三级综合医院眼科或二级及以上眼科专科医院医师处方；2.首次处方时病眼基线矫正视力0.05-0.5；3.事前审查后方可用，初次申请需有血管造影或OCT（全身情况不允许的患者可以提供OCT血管成像）证据；4.每眼累计最多支付9支，第1年度最多支付5支。阿柏西普、雷珠单抗和康柏西普的药品支数合并计算。","是","是"]
[{"$nulls":5},"乙",206,"阿柏西普眼内注射溶液","*；","*","限以下疾病：1.50岁以上的湿性年龄相关性黄斑变性（AMD）；2.糖尿病性黄斑水肿（DME）引起的视力损害。应同时符合以下条件：1.需三级综合医院眼科或二级及以上眼科专科医院医师处方；2.首次处方时病眼基线矫正视力0.05-0.5；3.事前审查后方可用，初次申请需有血管造影或OCT（全身情况不允许的患者可以提供OCT血管成像）证据；4.每眼累计最多支付9支，第1年度最多支付5支。阿柏西普、雷珠单抗和康柏西普的药品支数合并计算。","是","是"]
[{"$nulls":5},"乙",207,"雷珠单抗注射液","*；","*","限以下疾病：1.50岁以上的湿性年龄相关性黄斑变性（AMD）；2.糖尿病性黄斑水肿（DME）引起的视力损害；3.脉络膜新生血管（CNV）导致的视力损害；4.继发于视网膜静脉阻塞（RVO）的黄斑水肿引起的视力损害。应同时符合以下条件：1.需三级综合医院眼科或二级及以上眼科专科医院医师处方；2.首次处方时病眼基线矫正视力0.05-0.5；3.事前审查后方可用，初次申请需有血管造影或OCT（全身情况不允许的患者可以提供OCT血管成像）证据；4.每眼累计最多支付9支，第1年度最多支付5支。阿柏西普、雷珠单抗和康柏西普的药品支数合并计算。","是","是"]
["XS01X",null,null,"其他眼科用药"]
[{"$nulls":5},"乙",208,"环孢素滴眼液（Ⅱ）","5.5元（0.4ml∶0.2mg/支）","5.5元（0.4ml∶0.2mg/支）","本品可促进干眼症患者的泪液分泌，适用于与角结膜干燥症相关的眼部炎症所导致的泪液生成减少的患者。","否"]
["XV","其他"]
["XV03",null,"其他治疗药物"]
["XV03A",null,null,"其他治疗药物"]
["XV03AE",{"$nulls":3},"高血钾和高磷血症治疗药"]
[{"$nulls":5},"乙",209,"环硅酸锆钠散","*；","*","本品适用于治疗成人高钾血症。使用限制：因起效迟缓，本品不应该用于危及生命的高钾血症的紧急治疗。","否","是"]
["XV08",null,"造影剂"]
["XV08C",null,null,"磁共振成像造影剂"]
[{"$nulls":5},"乙",210,"钆特醇注射液","106.89元(10ml/支)；\n145.8元(15ml/支)；\n181.72元(20ml/支)","106.89元(10ml/支)；\n145.8元(15ml/支)；\n181.72元(20ml/支)",null,"否"]
[{"$nulls":5},"乙",211,"钆布醇注射液","*；","*",null,"否","是"]
["XV08D",null,null,"超声造影剂"]
[{"$nulls":5},"乙",212,"注射用全氟丙烷人血白蛋白微球","*；","*","用于常规超声心动图显影不够清晰者，增强显像效果，增加病变识别率及病变定性的准确性，增强左心室内膜边界的识别。","否","是"]
[{"$nulls":5},"乙",213,"注射用全氟丁烷微球","*；","*","本品仅用于诊断使用：注射用全氟丁烷微球是一种超声造影剂，用于肝脏局灶性病变血管相和Kupffer相的超声成像。","否","是"]

{"sheet":"中成药","index":1,"n_rows":112,"n_cols":11,"rows_kept":112,"merged":[[0,0,0,10],[1,0,2,0],[1,1,2,5],[1,6,2,6],[1,7,2,7],[1,8,2,8],[1,9,2,9],[1,10,2,10],[10,3,10,5],[36,4,36,6],[111,0,111,10]]}
["湖北省“双通道”及“单独支付\"药品目录（2022年版）\n（二）中成药"]
["药品分类代码","药品分类",{"$nulls":4},"编号","药品名称","医保支付标准","备注","是否单独支付"]
[]
["ZA","内科用药"]
["ZA01",null,"解表剂"]
["ZA01B",null,null,"辛凉解表剂"]
[{"$nulls":5},"乙",214,"牛黄清感胶囊","0.66元(0.3g/粒)",null,"否"]
[{"$nulls":5},"乙",215,"柴芩清宁胶囊","1.5元(0.3g/粒)",null,"否"]
[{"$nulls":5},"乙",216,"疏清颗粒","1.28元(3g/袋)；\n2.18元(6g/袋）",null,"否"]
["ZA03",null,"泻下剂"]
["ZA03B",null,null,"润肠通便剂"]
[{"$nulls":5},"乙",217,"芪黄通秘软胶囊","1.83元(0.5g/粒)","益气养血，润肠通便。用于功能性便秘证属虚秘者。","否"]
["ZA04",null,"清热剂"]
["ZA04A",null,null,"清热泻火剂"]
[{"$nulls":5},"乙",218,"清胃止痛微丸","3.55元(3.2g/袋)",null,"否"]
[{"$nulls":5},"乙",219,"熊胆舒肝利胆胶囊","0.98元(0.5g/粒)",null,"否"]
["ZA04B",null,null,"清热解毒剂"]
[{"$nulls":5},"乙",220,"冬凌草滴丸","0.19元(40mg/丸)","限放疗后急性咽炎的轻症患者。","否"]
[{"$nulls":5},"乙",221,"金银花口服液","3.08元(10ml/支)；\n5.24元(20ml/支)",null,"否"]
[{"$nulls":5},"乙",222,"热炎宁合剂","17.96元(100ml/瓶(每1ml相当于饮片1.30g))",null,"否"]
[{"$nulls":5},"乙",223,"蓝芩口服液","2.62元(10ml/支)；\n5.88元(10ml/支（相当于原药材21.2g))",null,"否"]
["ZA04C",null,null,"清脏腑热剂"]
["ZA04CA",{"$nulls":3},"清热理肺剂"]
[{"$nulls":5},"乙",224,"痰热清胶囊","4.09元(0.4g/粒)",null,"否"]
["ZA04CC"]
[{"$nulls":4},"清肝胆湿热剂"]
[{"$nulls":5},"乙",225,"鸡骨草胶囊","0.56元(0.5g/粒)",null,"否"]
[{"$nulls":5},"乙",226,"利胆止痛胶囊","0.41元(0.4g/粒)",null,"否"]
["ZA04CD",{"$nulls":3},"清利肠胃湿热剂"]
[{"$nulls":5},"乙",227,"五味苦参肠溶胶囊","2.68元(0.4g/粒)",null,"否"]
["ZA06",null,"化痰、止咳、平喘剂"]
["ZA06B",null,null,"理肺止咳剂"]
["ZA06BC",{"$nulls":3},"宣肺止咳剂"]
[{"$nulls":5},"乙",228,"小儿荆杏止咳颗粒","10.98元(5g(相当于饮片18.33g)/袋)",null,"否"]
[{"$nulls":5},"乙",229,"连花清咳片","1.29元(0.46g/片)",null,"否"]
["ZA06C",null,null,"清热化痰剂"]
["ZA06CA",{"$nulls":3},"清热化痰止咳"]
[{"$nulls":5},"乙",230,"金花清感颗粒","8.9元(5g（(相当于饮片17.3g)）/袋)","疏风宣肺，清热解毒。用于单纯型流行性感冒轻症，中医辨证属风热犯肺证者，症见发热，头痛，全身酸痛，咽痛，咳嗽，恶风或恶寒，鼻塞流涕，舌质红，舌苔薄黄，脉数。在新型冠状病毒肺炎的常规治疗中，可用于轻型、普通型引起的发热、咳嗽、乏力。","否"]
[{"$nulls":5},"乙",231,"化湿败毒颗粒","9.9元（5g（相当于饮片17.13g）/袋）","化湿解毒，宣肺泄热。用于湿毒侵肺所致的疫病，症见发热、咳嗽、乏力、胸闷、恶心、肌肉酸痛、咽干咽痛、食欲减退、口中粘腻不爽等。","否"]
[{"$nulls":5},"乙",232,"宣肺败毒颗粒","*；","宣肺化湿，清热透邪，泻肺解毒。用于湿毒郁肺所致的疫病。症见发热，咳嗽，咽部不适，喘促气短，乏力，纳呆，大便不畅；舌质暗红，苔黄腻或黄燥，脉滑数或弦滑。","否"]
[{"$nulls":5},"乙",233,"麻芩消咳颗粒","4.79元(8g/袋)",null,"否"]
[{"$nulls":5},"乙",234,"射麻口服液","3.98元(10ml/支)",null,"否"]
["ZA06CC",{"$nulls":3},"清热化痰止惊"]
[{"$nulls":5},"乙",235,"小儿牛黄清心散","2.36元(0.3g/袋)；\n4.01元(0.6g/袋)","限高热神昏的急救、抢救时使用。","否"]
["ZA08",null,"固涩剂"]
["ZA08B",null,null,"固涩止泻剂"]
[{"$nulls":5},"乙",236,"缓痛止泻软胶囊","2.98元(0.65g/粒)",null,"否"]
["ZA09",null,"扶正剂"]
["ZA09A",null,null,"补气剂"]
[{"$nulls":5},"乙",237,"甘海胃康胶囊","0.4元(0.4g/粒)",null,"否"]
["ZA09F",null,null,"气血双补剂"]
[{"$nulls":5},"乙",238,"百令胶囊","0.51元(0.2g/粒)；\n1.03元(0.5g/粒)","限器官移植抗排异、肾功能衰竭及肺纤维化。","否"]
["ZA09G",null,null,"益气养阴剂"]
[{"$nulls":5},"乙",239,"参乌益肾片","1.30元(0.4g/片)","限慢性肾衰竭患者。","否"]
[{"$nulls":5},"乙",240,"芪黄颗粒","7.5元(5g/袋)",null,"否"]
[{"$nulls":5},"乙",241,"桑枝总生物碱片","4.88元(50mg/片)",null,"否"]
[{"$nulls":5},"乙",242,"通脉降糖胶囊","0.47元(0.4g/粒)",null,"否"]
[{"$nulls":5},"乙",243,"参龙宁心胶囊","0.36元(0.5g/粒)","限冠心病和成年人恢复期病毒型心肌炎出现的轻度或中度室性过早搏动见上述证候者。","否"]
["ZA09H",null,null,"益气复脉剂"]
[{"$nulls":5},"乙",244,"注射用益气复脉(冻干)","16.5元(0.65g/瓶)","限二级及以上医疗机构冠心病心绞痛及冠心病所致左心功能不全II-III级的患者，单次住院最多支付14天。","否"]
["ZA12",null,"祛瘀剂"]
["ZA12A",null,null,"益气活血剂"]
[{"$nulls":5},"乙",245,"八味芪龙颗粒","2.93元(6g/袋)","限中风病中经络（轻中度脑梗塞）恢复期患者。","否"]
[{"$nulls":5},"乙",246,"杜蛭丸","6.49元(5g/25粒)","限中风病中经络恢复期患者。","否"]
[{"$nulls":5},"乙",247,"脑心安胶囊","1.38元(0.3g/粒)","限中重度脑梗塞、冠心病心绞痛患者。","否"]
[{"$nulls":5},"乙",248,"芪丹通络颗粒","4.16元(8g/袋)",null,"否"]
[{"$nulls":5},"乙",249,"芪芎通络胶囊","0.69元(0.5g/粒)","限中风病中经络（轻中度脑梗塞）恢复期患者。","否"]
[{"$nulls":5},"乙",250,"心脉隆注射液","26元(2ml:100mg/支)","限二级及以上医疗机构慢性心力衰竭患者。","否"]
[{"$nulls":5},"乙",251,"蒺藜皂苷胶囊","3.07元(65mg/粒)","限中风病中经络（轻中度脑梗死）恢复期患者。","否"]
["ZA12C",null,null,"养血活血剂"]
[{"$nulls":5},"乙",252,"丹红注射液","4.94元(2ml/支)；\n16.92元(10ml/支)；\n28.76元(20ml/支)","活血化瘀，通脉舒络。用于瘀血闭阻所致的胸痹及中风，证见：胸痛，胸闷，心悸，口眼歪斜，言语蹇涩，肢体麻木，活动不利等症；冠心病、心绞痛、心肌梗塞，瘀血型肺心病，缺血性脑病、脑血栓。","否"]
["ZA12I",null,null,"活血消癥剂"]
[{"$nulls":5},"乙",253,"蛭蛇通络胶囊","1.65元(0.5g/粒)","限中风病中经络(轻中度脑梗塞)恢复期气虚血瘀证。"," 否"]
["ZA12G",null,null,"化瘀宽胸剂"]
[{"$nulls":5},"乙",254,"西红花总苷片","16.5元(12mg/片)","限化疗产生心脏毒性引起的心绞痛患者。","否"]
[{"$nulls":5},"乙",255,"注射用丹参多酚酸","54.41元(0.13g/支)","限二级及以上医疗机构脑梗死恢复期患者，单次住院最多支付14天。","否"]
[{"$nulls":5},"乙",256,"注射用丹参多酚酸盐","31.69元(每瓶装50mg(含丹参乙酸镁40mg))；\n53.88元(每瓶装100mg(含丹参乙酸镁80mg))；91.60元(每瓶装200mg(含丹参乙酸镁160mg))","限二级及以上医疗机构并有明确冠心病稳定型心绞痛诊断的患者。","否"]
["ZA12H",null,null,"化瘀通脉剂"]
[{"$nulls":5},"乙",257,"血必净注射液","22.08元(10ml/支)","限二级及以上医疗机构重症患者的急救抢救。","否"]
[{"$nulls":5},"乙",258,"银杏内酯注射液","19.68元(2ml/支)","限二级及以上医疗机构脑梗死恢复期患者，单次住院最多支付14天。","否"]
[{"$nulls":5},"乙",259,"银杏二萜内酯葡胺注射液","93.7元(5ml/支)","限二级及以上医疗机构脑梗死恢复期患者，单次住院最多支付14天。","否"]
[{"$nulls":5},"乙",260,"丹灯通脑软胶囊","0.64元(0.55g/粒)",null,"否"]
["ZA15",null,"治风剂"]
["ZA15B",null,null,"平肝熄风剂"]
[{"$nulls":5},"乙",261,"芍麻止痉颗粒","13.24元(2.5g(相当于饮片9.4g)/袋)；\n22.5元(5g(相当于饮片18.8g)/袋)",null,"否"]
["ZA15E",null,null,"化瘀祛风剂"]
[{"$nulls":5},"乙",262,"川芎清脑颗粒","3.33元(10g/袋)",null,"否"]
["ZA17",null,"化浊降脂剂"]
[{"$nulls":5},"乙",263,"降脂通络软胶囊","0.72元(50mg/粒)","限高脂血症属血瘀气滞证者。","否"]
["ZC","肿瘤用药"]
["ZC01",null,"抗肿瘤药"]
[{"$nulls":5},"乙",264,"复方黄黛片","10.19元(0.27g/片)","限初治的急性早幼粒细胞白血病。","是"]
[{"$nulls":5},"乙",265,"食道平散","163元(10g/瓶)","限中晚期食道癌所致食道狭窄梗阻的患者。","否"]
[{"$nulls":5},"乙",266,"康莱特注射液","136元(100ml:10g/支)","限二级及以上医疗机构中晚期肺癌或中晚期肝癌。","否"]
[{"$nulls":5},"乙",267,"康艾注射液","11.73元(5ml/支)；\n19.94元(10ml/支)；\n33.9元(20ml/支)","限二级及以上医疗机构说明书标明恶性肿瘤的中晚期治疗。","否"]
["ZC02",null,"肿瘤辅助用药"]
[{"$nulls":5},"乙",268,"参一胶囊","6.18元(每粒含人参皂苷Rg3 10mg)","限原发性肺癌、肝癌化疗期间使用。","否"]
[{"$nulls":5},"乙",269,"注射用黄芪多糖","200元(250mg/支)","限二级及以上医疗机构肿瘤患者，单次住院最多支付14天。","否"]
["ZG","骨伤科用药"]
["ZG01",null,"活血化瘀剂"]
[{"$nulls":5},"乙",270,"五虎口服液","11.6元(10ml/支)",null,"否"]
["ZG02",null,"活血通络剂"]
[{"$nulls":5},"乙",271,"筋骨止痛凝胶","55元(15g/支)",null,"否"]
["ZD","妇科用药"]
["ZD03",null,"扶正剂"]
[{"$nulls":5},"乙",272,"关黄母颗粒","4.28元（9g（相当于饮片4.8g）/袋）","补益肝肾，滋阴降火。用于女性更年期综合征(绝经前后诸证)中医辨证属肝肾阴虚证，症见烘热汗出，头晕，耳鸣，腰膝酸软或足跟痛，少寐多梦，急躁易怒等。","否"]
["ZI","民族药"]
["ZI01",null,"藏药"]
[{"$nulls":5},"乙",273,"安儿宁颗粒","1.98元(3g/袋)",null,"否"]
[{"$nulls":5},"乙",274,"红花如意丸","0.7元(0.2g/丸)",null,"否"]
[{"$nulls":5},"乙",275,"如意珍宝片","1.87元(0.5g/片)",null,"否"]
["备注：企业申请价格保密的，医保支付标准一栏标识为*。"]